

# Determining the Economic Suitability of a Variable Annuity Transaction

AUGUST 2016 | REVISED MARCH 2017

**CANNEX**



# TABLE OF CONTENTS

Introduction & Summary .....	2
Why Do People Buy Variable Annuities? .....	3
How Do Living Benefits Work? .....	4
Challenges in Comparing Variable Annuities .....	5
Valuation Methodology for Economic Suitability .....	6
Transaction Case Studies .....	10
1035 Exchange / Transfer Evaluation.....	11
Buyout Offer Evaluation .....	14
New Sale / New Money Evaluation.....	19
Aligning Valuation with Current Practices.....	22
Conclusion .....	23
References .....	24

## INTRODUCTION AND SUMMARY

Variable annuities (VAs) are the most popular form of annuity purchased in the U.S. market today, and the majority of those sold—over 70%—contain some form of living benefit rider which allows the purchaser to “turn on” an option to receive regular income from the annuity.

Compared to other savings and retirement products, variable annuities are complex products. As a result VA sales are subject to considerable scrutiny by U.S. regulators. In recent years, sizeable fines resulting from inadequate controls or procedures to monitor the suitable sale of these products have been imposed on broker-dealers by the Financial Industry Regulatory Authority (FINRA).

More recently, the Department of Labor (DOL) has announced a proposed new fiduciary standard whereby the advisor—or rather, their firm—will have to deliver proof that the recommendation of a VA is in the “best interest” of a client rather than being merely “suitable.”

Those factors—the popularity of VAs, their complexity and the expanding requirement to demonstrate the benefit to clients of a VA transaction—lead to a need on the part of financial advisors (and their firms) for a way to transparently assess a proposed VA transaction. However, this need is hard to fulfill. The challenge in assessing the potential benefit (or cost) of a VA transaction stems from two primary reasons:

**The first** is a cost comparison issue which arises when the size and scope of various fees and expenses in a VA contract or contracts do not directly correlate to the benefits received by the client. Similarly, the size and scope of rates set out in a VA contract (i.e., a guaranteed withdrawal rate, a roll-up rate, and so on) may not necessarily correlate to the size of the benefit to the client. For example, is a higher guaranteed withdrawal rate—6% versus 5%—(always) better than a lower rate? In some cases, depending on client and other circumstances, the answer is “no.”

**The second** challenge is a product alignment issue which arises when the performance of a specific product may work well for some people and in some circumstances and not so well for others. Said another way, the client profile, along with their intended use of the specific product or product features, can impact the value of the benefit they receive from the product. For any VA contract, all investors are not created equal.

Today, the primary tools available to assist an advisor with their due diligence for VA sales are either composite comparisons of static fees and product specifications for two or more products, or stand-alone illustrations obtained directly from each carrier which advisors can then use in efforts to compare products. In this paper we propose a scoring methodology for VA transactions that is intended to improve current evaluation practices—and empower financial institutions, their advisors and VA clients to make more informed decisions about these transactions.

In the remainder of this paper we provide an overview of:

- The challenges in evaluating various features available within VA contracts.
- A recommended approach to better allow an advisor and their firm to adequately and transparently assess the potential economic impact of a sale, exchange or termination of a VA contract.
- How to interpret the results of the application of this approach to some common or typical cases an advisor might encounter.

*Ultimately, it is our belief that by adopting the methodology we set out here, the **due diligence and product selection** processes for VA sales will be enhanced, thus improving the advisor's and firm's ability to meet compliance and regulatory obligations.*

## WHY DO PEOPLE BUY VARIABLE ANNUITIES?

Let's start by quickly reviewing the basics: An annuity contract consists of two components: the *deferral phase* and the *annuity phase*.

With an income annuity—otherwise known as a pension annuity—the deferral phase is specifically defined at purchase before a series of periodic payments begins at the start of the annuity phase. Income annuities include the single-premium income annuity, or SPIA; the deferred income annuity or DIA, and the qualified longevity annuity contract or QLAC.

With a deferred annuity—otherwise known as a savings annuity—the deferral phase is open-ended and not defined, and the annuity phase is rarely triggered. Deferred annuities include variable annuities, indexed annuities and fixed rate annuities. Deferred annuities are typically positioned in the marketplace as savings products that can be converted into guaranteed income later, if needed.

When first introduced into the market in the 1950s, VAs were sold as products that provided an investor with the ability to receive a *death benefit* on their fund investments. With a VA, as the funds were held inside an insurance contract, the investor received the additional benefit of tax deferral on earnings growth, as well as tax-free transfers between funds within the contract.

Towards the end of the twentieth century, the concept of an additional *living benefit* was introduced to VA contracts to provide greater flexibility on how guaranteed income might be provided from the contract.

Academics and retirement planning specialists have long known that using a portion of a client's assets to purchase an income or pension annuity can help mitigate various risks (such as longevity, for example) in retirement. Traditionally, however, investors have been wary of purchasing income annuities—or “committing to the annuity phase”—because of the loss of control of their assets which the annuity purchase or phase represents.

Enter the living benefit—which, in contrast to the traditional pension annuity, provides a way to offer guaranteed income (or maintain a future income level) during the deferral phase of the contract, while still providing access to the account value. The rise and evolution of the living benefit option within the VA market has much to do with the behavioral finance challenge of finding the appropriate trade-off between the individual's desire to maintain control and access to their savings versus the long-term need or preference to maintain the security of guaranteed lifetime income (See Figure 1 for an illustration of this trade-off and how various products are positioned along it).

**Figure 1: The Behavioral Trade-off for Income Solutions—Asset Control versus Income Security**



SWP = Systematic Withdrawal Plan  
GLB = Guaranteed Living Benefit

Many retirees may initially attempt to maintain as much control as possible over their assets in an Individual Retirement Account (IRA) or other investment accounts—meaning they generally avoid annuitizing their portfolios. However, by doing so, as retirement proceeds they may run the risk of outliving their nest egg and/or altering their lifestyle if investments do not perform as expected (or hoped).

Consistent with this finding, a majority of income annuity sales occur only when they are framed by the advisor as part of an overall portfolio which is itself part of a broader financial plan—but that sales process can involve a lot of time and effort (and trust) by both the advisor and the client<sup>1</sup>. With a living benefit, the client (and the advisor) can essentially have their cake and eat it too: asset control coupled with income security. But this easy “behavioral fix” (“the option is there if you need it or want it; you don’t need to decide or commit right now”) comes at a price. Some people are willing to pay for that future option.

Today, VA consumers have the option to buy one or both of a death benefit and living benefit embedded in the VA contract; and they will make their choice about purchasing these benefits depending upon the options presented to them, their financial planning needs and preferences, and how they value the convenience of packaging.

However, the valuation and comparison of the additional death benefit and living benefit within the VA contract can be very difficult to measure quantitatively—not only between competing variable annuity products, but against a combination of other products that could possibly service the same needs without the convenience of bundling and packaging.

## HOW DO LIVING BENEFITS WORK?

Today, the most popular form of living benefit in the market is the Guaranteed Lifetime Withdrawal Benefit (or GLWB). With this benefit, once an investor decides to start taking systematic withdrawals from their account, that withdrawal amount will be guaranteed for their lifetime, even if the account value falls to \$0.

Previously, when living benefits were first introduced in the market, the Guaranteed Minimum Income Benefit (GMIB) was the primary form of benefit. However, triggering this benefit ultimately required the investor to enter the annuity phase of the contract in order to receive periodic payments.

Whether you are contemplating the GLWB or the GMIB, in both cases the level of the payout benefit is partly determined by the performance of a “shadow account” within the VA contract, otherwise known as a benefit base. Over time, the value of this benefit base tends to increase, both as a result of an upward market performance of the underlying investments as well as from a number of stipulated rules and formulae defined within the VA contract itself. However, irrespective of the performance of the shadow account or benefit base, the living benefit continues to provide income for as long as the client is alive even if the underlying account on which the income was based has been exhausted.

In technical terms, a living benefit on a variable annuity can be thought of as an *exotic put option*<sup>2</sup> that is triggered when the contract enters the annuity phase—with the option triggered either automatically (for a GLWB when the account value is exhausted) or manually (for a GMIB within a defined time frame).

<sup>1</sup> That said, it’s worth noting that our research has shown that the allocation of a VA with a Living Benefit along with investments and an income annuity (i.e., all 3) can further optimize a retirement portfolio whereby the VA acts as a pendulum between growth and a guarantee. In good markets, the VA performs like an investment and in bad markets it performs more like an income annuity.

<sup>2</sup> Huang, H., Milevsky, M. and Salisbury, T. Complete Market Valuation of the Ruin-Contingent Life Annuity (RCLA). *Journal of Risk and Insurance* (January 16, 2009)

## **CHALLENGES IN COMPARING VARIABLE ANNUITIES**

In today's market, the sale of a variable annuity is generally supported with a presentation of product specifications, accompanied by illustrations that provide deterministic scenarios (i.e., no incorporation of randomness), that together endeavor to depict potential future outcomes of the proposed investment.

A comparative assessment of two or more products will usually focus on the specifications for fees as well as an evaluation of the nominal rider benefits (e.g., a roll-up rate of 5%). Comparing product illustrations can be challenging, however, as capital market assumptions and other pricing variables are not consistent from carrier to carrier.

We have identified three main challenges which can cloud efforts to provide transparent and straightforward assessments of the economic value of a proposed VA transaction for the purchaser:

### ***CHALLENGE 1: THE LEVEL OF FEES AND EXPENSES DOES NOT CORRELATE TO THE LEVEL OF BENEFIT RECEIVED BY THE INVESTOR***

As part of the sales and compliance process, advisors compare a variety of fees—including Mortality & Expense (M&E), sales/contingent deferred sales charges (CDSC), rider fees and fund management fees.

Sometimes, the focus on fees and charges is emphasized to such a degree that the transaction is evaluated through that lens only. However, even with a close focus on fees and costs it can be very difficult to understand how the fees and charges in one contract will impact how that contract might perform against another contract with its own set of fees and charges.

Based on our experience with extensive case analysis, and as noted earlier our conclusion is that various fees often do not correspond directly with the individual benefits that are offered within the product—and, somewhat counterintuitively, higher contract fees do not always mean the client is worse off.

### ***CHALLENGE 2: BIGGER IS NOT ALWAYS BETTER***

Another area of potential confusion in assessing VA contracts is understanding the value of the embedded benefits that may be purchased with a new contract or surrendered with an existing one. Similar to the fee issue, a higher withdrawal rate or roll-up rate, while they may appear superficially attractive and beneficial, do not necessarily equate to a better outcome for the client. Instead, a deeper quantitative look is needed to be able to differentiate among many features, their value and their usefulness to the particular individual.

### ***CHALLENGE 3: DIFFERENT COMBINATIONS PRODUCE DIFFERENT RESULTS***

Finally, the outcomes from a contract derived from the unique combination of rider specifications with defined rules and parameters within a product are not at all obvious. For example, a contract may have three different share class options, three GLWB options and two death benefit options (in addition to other fee variations based on state, premium amounts, and more).

That set represents 18 potential combinations which, based on our research and experience, will produce a wide variety of outcomes. But that range of combinations is only based on the product specifications—when the profile of the client (i.e., age and gender) is added and combined with an anticipated start date for income, the variability expands even further.

The client and advisor, who are trying to determine the best choice for the client, are left with an unwieldy set of alternatives for which the impact of various levers and dials (change the income start date? choose a different GLWB or death benefit option?) is largely opaque.

## VALUATION METHODOLOGY FOR ECONOMIC SUITABILITY

Now that we have laid out the primary challenges in assessing the suitability of a VA transaction, let's return to first principles for a moment: consider that a variable annuity is a long-term investment primarily designed to support retirement needs (e.g., retirement income, estate planning, etc.). Therefore our (and an advisor's) main objective in reviewing a potential VA transaction must be to assess the economic suitability of the transaction given the intended nature of these products, versus any ancillary benefit or function that these contracts might fulfill.

In order to accomplish this task, it is essential that first, the assessment is consistent from a financial and actuarial perspective—that is, it must be replicable from product to product and across different economic environments—and next, that the results be communicated in a simple and transparent manner which highlights the basic components of the contract that have been bundled together.

This is where CANNEX's methodology for evaluating and scoring proposed VA transactions in the context of retirement income and estate planning comes in. Our analysis includes three main steps: first, determining the present economic value of a specific VA contract; secondly, exploring the variability of the values around the average economic value; and finally determining the net economic value of a proposed VA transaction or comparing a group of VA contracts individually by their values. This multi-step approach allows advisors and their clients to move beyond the current practices for evaluating and recommending VA transactions, in which advisors rely on qualitative analysis of potential outcomes, and towards a robust, transparent, and repeatable quantitative methodology for reviewing, assessing and recommending VA transactions.

Note that the magnitude and structure of various fees can be a significant factor when valuation is performed. When comparing product specifications side by side one can easily spot any nominal difference in fees between products, however, it is important to fully understand what an investor is actually receiving for a certain fee (what does each feature provide, relative to its cost?). Our valuation assessment can help a decision-maker understand this relationship by incorporating the cumulative effects of various fees onto each of the components of the economic value. We outline the three steps in our methodology here:

### ***STEP 1: DETERMINE THE ECONOMIC VALUE OF A VA CONTRACT***

Fundamentally, our analysis focuses on the three primary "exit options" available with a VA. A client can leave or discard a VA contract by surrendering it, dying, or taking income. So, in our approach we quantitatively compare the surrender options, death benefit, and income benefit of two (or more) variable annuity contracts taking into consideration:

- The value of the sub-accounts (i.e., the account value)
- The value of the "shadow accounts" (i.e., the benefit base for the death and living benefit riders)
- Product features in the base contract, as well as in the death and living benefit riders
- Any CDSC / surrender fees and their schedules
- Base contract fees and rider fees
- Market returns and volatility
- Expected mortality given the client's demographic profile (age and gender)

We then model the expected performance of each product over time to the best extent possible while focusing on market performance and client demographics. By doing so we not only can tell if one product is a better investment vehicle considered on its own merit, but we can also go deeper into the analysis and help determine the economic benefit for a particular client based on their situation, needs and preferences.



More precisely, our economic suitability analysis involves first, decomposing a variable annuity into a portfolio of embedded guarantees and secondly, computing their respective values using option pricing methodology. The analysis is performed using the techniques of Monte Carlo simulations and the outcome of the analysis focuses mainly on the valuation of the downside protections, income benefits, and life insurance protections embedded in the contract.

Our analysis breaks a variable annuity contract into the following components:

**LAPSE VALUE:** This represents the actuarial present value to the client of the flexibility to exit the contract at any point of time. This value is highly dependent on the CDSC schedule provisioned in the contract, the number of years the client has held the product, and industry lapse experience. Generally speaking, the client may be more likely to surrender the contract upon termination of the CDSC period. From this we can conclude that the lapse value is lower for a product that is within its surrender charge period compared to the one for which the surrender period has been completed.

**DEATH VALUE:** This represents the actuarial present value of the life insurance component of the VA that is provided to the estate upon the death of the policy owner. It is determined based on the relationship between the death benefit base and the account value at the time of death. The value of the death benefit base is mostly driven by rider provisions such as crediting, reset frequency, reset provisions, and any additional deposits and withdrawals.

**INCOME VALUE:** This represents the actuarial present value of future income derived from the VA, assuming that the maximum allowable withdrawals are taken, such that the benefit base is not negatively impacted. The income that the client is expected to receive from a Guaranteed Lifetime Withdrawal Benefit, for example, is determined in large part by two factors: the withdrawal rate and the income benefit base. The value of the income benefit base is also tied to the account value, rider provisions, reset frequency, crediting rates, and rider fees.

**Figure 2: Example of Economic Value Assessment**

<b>Economic Value Component</b>	
Lapse / Surrender	\$39,600
Death Benefit	\$23,200
Income Benefit	\$53,100
<b>Economic Value</b>	<b>\$115,900</b>

**STEP 2: DETERMINE THE NET ECONOMIC VALUE OF A PROPOSED VA TRANSACTION**

The economic value of each VA contract is the aggregated value of each of the components noted in Step 1. We can use this value, once completed, to determine the net economic value of a proposed transaction (sale, surrender, exchange, lapse, or at death) by calculating the difference between the economic values of two VA contracts.

In general, a transaction is considered economically suitable if the net economic value is positive — see Figure 3 (next page) for a hypothetical example.

**Figure 3: Example of Economic Valuation for a 1035 Exchange**

	Product A		Product B	
	Value	$\sigma$	Value	$\sigma$
Lapse / Surrender	\$39,600	34%	\$40,800	34%
Death Benefit	\$23,200	40%	\$23,900	36%
Income Benefit	\$53,100	16%	\$54,600	16%
<b>Economic Value</b>	<b>\$115,900</b>	<b>32%</b>	<b>\$119,300</b>	<b>30%</b>
<b>Net Economic Value: \$3,400</b>				

In the case of a new annuity transaction, this analysis can also be applied across a group of contracts accordingly (see Figure 4 for a hypothetical sample).

**Figure 4: Comparing a Group of Contracts**

	Economic Value		Lapse/Surrender		Death Benefit		Income Benefit	
	Value	$\sigma$	Value	$\sigma$	Value	$\sigma$	Value	$\sigma$
Product A	\$115,900	32%	\$39,600	34%	\$23,200	40%	\$53,100	16%
Product B	\$119,300	30%	\$40,800	34%	\$23,900	36%	\$54,600	16%
Product C	\$114,600	32%	\$39,600	34%	\$29,500	31%	\$45,500	19%
Product D	\$112,000	32%	\$38,400	34%	\$14,600	61%	\$59,000	14%
Product E	\$124,000	33%	\$54,000	23%	\$20,300	43%	\$49,700	16%

**STEP 3: EXPLORE THE VARIABILITY (SIGMA) AROUND AVERAGE VALUES**

Whereas the economic value is the average of all of the Monte Carlo simulations, a standard deviation can also provide us with a measure of the variability of the outcomes around the average value (see Figure 5).

**Figure 5: Adding Standard Deviation to Economic Value Assessment**

	Product A	
Economic Value Component	Value	$\sigma$
Lapse / Surrender	\$39,600	34%
Death Benefit	\$23,200	40%
Income Benefit	\$53,100	16%
<b>Economic Value</b>	<b>\$115,900</b>	<b>32%</b>

A higher standard deviation value indicates that there is a greater variability or uncertainty around the outcome. A lower value, on the other hand, indicates lower variability, or lesser uncertainty around the economic value. Economic value together with its accompanying standard deviation provides a better or deeper view of the outcomes so that the investor is able to make a better-informed decision. The client should be aware of the variability of potential outcomes when assessing values between products.

Our analysis can also be carried out for specific guarantees allowing a client or advisor to focus on a single benefit compared across products based on a client's preferences or needs for liquidity, income, and/or financial legacy.

In addition, other "non-economic" needs and preferences may have an impact on the overall suitability of a transaction for a client. While these are not taken into consideration in this quantitative analysis, the individual components of the analysis can be drawn out from the economic analysis and considered in order to better align the product with planning needs expressed by the client (e.g., a preference for liquidity over a death benefit).

We note that this analysis is performed on a pre-tax basis, assuming that tax treatment is equal for all products—although there are some product designs that require some use of tax assumptions that impact the performance of a rider. Our standard analysis also assumes the same investment performance for each product while also recognizing that certain equity and volatility limitations may exist in certain cases. Think of an ammeter, used to measure current, which can be mounted in any position to get accurate measurements in electric power systems. Ultimately, the goal is to pass the same "electrical current" through the insurance policy to adequately measure the return (and uncertainty) associated with the contractual guarantees given the combination of riders and base contract options chosen by the investor.

In short: by breaking out the basic components of the contract, the advisor is in a better position to match (and document) the preferences of the client with the anticipated value they will receive.

## CASE STUDIES

For the remainder of this paper we will review case results for three common transactional scenarios: an annuity exchange, a buyout offer, and a new sale with new assets. The purpose of these cases is to highlight the differences (or gaps) between the existing qualitative practices of comparing specifications between products versus a quantitative assessment in which an economic valuation is performed. Each assessment can be positioned in a variety of ways depending upon the client profile and situation in which the transaction is taking place.

These cases are drawn from CANNEX’s experience in supporting suitability assessment processes for our clients.

Here we perform our case analysis on two model clients: Jill, a 67-year-old female, and Mark, a 73-year-old male. Both Jill and Mark have existing VA contracts from which they have decided to start receiving guaranteed income (via a GLWB) at the age of 71; an income start age that aligns with IRS minimum distribution requirements. This means that Mark has already triggered his income benefit, while Jill still has a few more years of accumulation before her income starts.

With respect to the products, for all three cases we will use a stylized representation of contracts that have been popular in the market—and which we’ll simply call “Product A” and “Product B.” For both sample products, we’ve included those specifications that we, through our research and experience, have determined could potentially have a material impact on the valuation analysis. The characteristics of our two sample products are summarized in Figure 6.

**Figure 6: Sample Variable Annuity Products with GLWB—Jill and Mark**

	Product A	Product B
<b>Base Contract Specifications</b>		
Mortality & Expense Fee (Tier 1)	0.95%	0.85%
Mortality & Expense Fee (Tier 2)	n/a	1.10% (at GLWB start)
Mortality & Expense Fee Frequency	Daily	Daily
Administrative Fee	0.20%	0.15%
Administrative Fee Frequency	Daily	Daily
Asset Management Fee	1.0%	1.0%
Asset Management Fee Frequency	Daily	Daily
CDSC Schedule (Year / Rate)	7%, 7%, 7%, 6%, 6%, 5%, 4%, 3%	5%, 4%, 3%, 2%, 1%
<b>Rider Specifications</b>		
<i>Living Benefit Rider</i>	GLWB Rider A	GLWB Rider B
Fee	0.75%	1.25%
Fee Frequency	Annually	Annually
Crediting Rate (i.e., Roll-Up)	n/a	5.0%
Step-Up Frequency	Annually	Annually
Withdrawal Rate (@ Income Start)	5.0% (Age < 65) 5.5% (Age 65 – 69) 6.0% (Age 70 – 74) 6.5% (Age 75 – 79) 7.0% (Age 80+)	4.3% (Age < 65) 5.3% (Age 65 – 79) 6.3% (Age 80+)
<i>Death Benefit Rider</i>	Standard DB Rider A	Standard DB Rider B
Fee	0.0%	0.0%
Rider Frequency	Annually	Annually
Step-Up Frequency	Monthly	Monthly

## CASE 1: ANNUITY EXCHANGE (OR REPLACEMENT)

Annuity replacements, also known as 1035 exchanges, account for approximately 50% of annuity sales each year, and are thus the focus of our first case<sup>3</sup>.

When performing an economic valuation of an annuity replacement, the primary objective is to understand the “moneyness” of the contract and what it means to the client when options are in the money or out of the money<sup>4</sup>. Recall that we stated earlier that our proposed approach for determining the economic suitability of a VA transaction uses option pricing methodology, and that we said a living benefit on a variable annuity can be thought of as a kind of exotic put option that is triggered when the contract enters the annuity phase.

In our analysis, we are using the term moneyness, and the associated options pricing methodology, to describe the relationship between the benefit base value and the actual account value. Our goal in adopting this approach is to understand the implications of moving from a benefit (or multiple benefits) that has been performing under an existing contract and determine the potential performance of that benefit if the existing contract was retained, or alternately if the benefit was “re-booted” within a new one.

Note also that when contemplating a section 1035 exchange, it is important to understand the client’s purpose for the exchange. Any features that are lost if an existing contract is exchanged may have been more valuable based on the accumulated imbedded value invested in that contract, compared with features in a new VA that may appear attractive but, in reality, have no material impact if they are not fully realized. For example: an enhanced death benefit in a new VA contract, while it could be characterized as an improvement over an existing contract, may provide meagre value to a client if her purpose for the product is to maximize living (not death) benefits.

In this case, Jill (age 67) will qualify for a guaranteed withdrawal rate of 6% under the old contract and 5.3% with the new contract based on her target income start at age 71 (as noted in Figure 7). Mark (age 73), on the other hand, will receive a withdrawal rate of 6.0% with the existing and 5.3% with the new contract given that he started taking income two years ago. The table in Figure 7 shows the values of the various accounts at the time of the transaction:

### a. Qualitative Assessment for Jill & Mark

**Figure 7: Account Values for Products A and B at the time of a Section 1035 Exchange**

	Product A (old)	Product B (new)
Account Value	\$171,500	\$171,500*
Income Benefit Base	\$244,010	\$171,500
Death Benefit Base	\$173,230	\$171,500

\*assumes no up-front sales charge

First, let’s attempt to assess the exchange decision for Jill by examining the comparative specifications of each product (as set out in Figure 4). Here we may observe the following:

#### PRODUCT A (EXISTING PRODUCT)

- A CDSC Fee would not apply since both Jill and Mark are outside of the surrender charge period
- The total fees for the existing contract (Product A) are higher than Product B

<sup>3</sup> A Section 1035 Exchange refers to the replacement of an annuity or life insurance policy for a new one without incurring any tax consequence for the exchange. The IRS allows holders of these types of contracts to do this in order to replace outdated contracts with new contracts with improved benefits, lower fees and different investment options. Section 1035 is a provision of the U.S. tax code that gives a policyholder the ability to transfer funds from a life insurance, endowment or annuity to a policy of a similar type.

<sup>4</sup> In finance, moneyness is the relative position of the current price (or future price) of an underlying asset with respect to the strike or exercise price of a derivative, most commonly a call option or a put option. Moneyness is understood as a three-fold classification: if the current price of the underlying asset is greater than the exercise price, then the option is said to be “in-the-money”; if the current price is less than the exercise price, then it is “out-of-the-money”; if equal, then it is “at-the-money”.

- The living benefit for Product A is quite valuable given that the income benefit base is substantially higher than the account value, plus:
  - the living benefit rider fee is 50 bps lower than Product B
  - the withdrawal rate will be higher if Jill and Mark stay with Product A
- The death benefit base is slightly higher than the account value. This implies that this benefit is not as valuable given that Jill still has four years to go until she starts income. In all likelihood the account value will surpass the death benefit base and a higher watermark will be locked in (if Jill keeps Product A until income begins).

*PRODUCT B (PROPOSED PRODUCT)*

- The benefit bases will be equal to the account value upon purchase of the new contract (in this case, there are no up-front sales charges associated with the new product)
- For the living benefit, there is an additional crediting rate (i.e., Roll-Up) of 5% that is applied annually. However, the withdrawal rate associated with both Jill's and Mark's income start is 5.3%—which is slightly lower than Product A.

*CONCLUSION*

- Overall, based on this qualitative analysis, the recommendation for both Jill and Mark may be to not proceed with the exchange transaction due to the following reasons:
  - Product A has a higher income-generating potential due to a higher benefit base as well as a higher withdrawal rate,
  - Product A has a higher death benefit base, and
  - Product A provides more flexibility to surrender the contract.

**b. Quantitative Assessment for Jill (Economic Valuation)**

Now let's examine what the recommendation may look like when running both products through an independent analytical process to determine the value of the guarantees embedded in the two products.

**Figure 8: Economic Valuation for Jill — 1035 Exchange**

	Product A (old)		Product B (new)	
	Value	$\sigma$	Value	$\sigma$
Lapse / Surrender	\$69,400	28%	\$62,100	37%
Death Benefit	\$30,700	45%	\$38,000	42%
Income Benefit	\$92,500	14%	\$74,200	18%
<b>Economic Value</b>	<b>\$192,600</b>	<b>29%</b>	<b>\$174,300</b>	<b>36%</b>
<b>Net Economic Value: (\$18,300)</b>				

Now we observe that the overall net economic value of the transaction is negative—and not only that, the uncertainty around the net economic value has gone up, as reflected by the increase in the standard deviation.

However, one area of improvement is the value of legacy (or death benefit). If the primary purpose of this transaction was focused on an improvement in the death benefit, then this transaction was beneficial to the client.

On other hand, if income generation was the primary objective, then this transaction is clearly futile despite the generous base crediting (i.e., the roll-up rate) that Jill would receive during the accumulation phase of the new product before starting the withdrawal benefit in four years. Her existing product would likely produce a better income benefit over time due to the step-ups (i.e., high-water marks) and accumulated value already achieved with the benefit base while the original contract is in force—this is what we meant by the idea that the client's accumulated embedded benefit in the product has value.

### c. Quantitative Assessment for Mark (Economic Value)

Now let's see how the same transaction would be assessed for Mark—given his client profile, and the fact that he has already started taking income from the existing contract.

**Figure 9: Economic Valuation for Mark — 1035 Exchange**

	Product A (old)		Product B (new)	
	Value	$\sigma$	Value	$\sigma$
Lapse / Surrender	\$42,000	25%	\$38,300	36%
Death Benefit	\$36,100	34%	\$58,000	31%
Income Benefit	\$107,000	5%	\$75,300	11%
<b>Economic Value</b>	<b>\$185,100</b>	<b>18%</b>	<b>\$171,600</b>	<b>26%</b>
<b>Net Economic Value: (\$13,500)</b>				

Overall, in Mark's case the impact to the death and income benefits would be the same as in Jill's case; and produce a negative net economic value for the transaction. However, the variability of the income benefit value for Mark is smaller, compared to Jill's transaction. This is most probably due to the fact that Mark was already taking income from his existing VA and the new income benefit from the new product started immediately upon the exchange.

Also of note, the increase in death benefit value was greater than in Jill's case. All in all, the assessment and transaction recommendation is the same for both, i.e. the exchange is not in the best interest of the clients.

### d. Summary of Case 1 Results

For Case 1, one view would be that the quantitative analysis validates the original qualitative assessment and the ultimate recommendation to not proceed with the transaction. However, if the client had indicated that improvement of the death benefit was more important than other factors, then there may be a reason to complete the exchange. The quantitative valuation, as performed above, helps to explore and would help to justify the transaction in an objective manner based on economic, financial, and actuarial principles.

Looking at Case 1 as a whole, the following table (in Figure 10) summarizes the results of the qualitative and quantitative assessment for Jill and Mark (above) and highlights the situations where the qualitative assessment and quantitative analysis do not agree.

**Figure 10: Qualitative and Quantitative Methods to Assess a Proposed VA Exchange: How do the two methods compare?**

		Which is better?	
		Qualitative Comparison of Products A & B (Specifications)	Quantitative Comparison of Products A & B (Net Economic Value)
Jill	Surrender Value	A	A
	Death Benefit	A	B
	Income Benefit	A	A
	Overall Benefit	A	A
Mark	Surrender Value	A	A
	Death Benefit	A	B
	Income Benefit	A	A
	Overall Benefit	A	A

In this case, the economic valuation process helps the advisor meet their compliance and regulatory obligations by proving (or disproving) the economic benefit of a transaction for their client, taking into account the client's preferences.

## CASE 2: BUYOUT OFFER

Product manufacturers have the ability to provide a cash incentive for a client to surrender, transfer or purchase a new product. In this case, we want to assess whether or not a cash offer to surrender a contract is in the best interest of the client—regardless of whether the buyout is being offered by the provider of the new contract or the old.

Here we take a closer look into exactly how large the buyout offer needs to be in order to sufficiently cover the lost benefit from a surrendered contract. In this case, we will look at a range of typical or plausible cash buyout offers of between \$15k and \$50k. In some situations there may be a trade-off in the valuations between the income benefit and a death benefit. Ultimately the transaction is beneficial when the valuation is higher across all of the economic value components.

For this case we will use the same two products from the previous case (in Figure 4) and again consider the impact of the transaction for Jill (age 67) and Mark (age 73). The starting values for each product will also be similar, but we will add a buyout offer received immediately as the exchange is completed. It is important to mention that we will be adding the cash incentive to the account value of the new product only. Here we expect to see an increase in the total economic value of the new product, as well as all of its components to a certain degree. However, one should not expect an increase in value for the exact amount of the cash incentive due to the fact that the calculations are averaged across multiple random scenarios. Figure 11 shows an array of buyout offers from \$15k to \$50k.

**Figure 11: Comparing Products A and B when a cash buyout offer is added**

	Product A (old)	Product B (new)
Account Value	\$171,500	\$171,500
Income Benefit Base	\$244,010	\$171,500
Death Benefit Base	\$173,230	\$171,500
Buyout Offer	Option 1 = \$15,000 Option 2 = \$20,000 Option 3 = \$30,000 Option 4 = \$40,000 Option 5 = \$50,000	n/a

### a. Qualitative Assessment for Jill and Mark

As in the first case, let's start with a qualitative effort to assess the decision to accept the buyout offer by examining the comparative specifications of each product. We are trying to determine how large the incentive should be for the transaction to be economically valuable.

The results of our qualitative assessment from Case 1 are still valid for this buyout situation. What we're now attempting to determine is whether or not a \$25k buyout offer is good enough to improve the income benefit; and secondly, how a buyout would impact the death benefit. Clearly the buyout amount is sizable compared to the account value, but is it enough to make up for the benefit accumulated in Product A (lost if the product is exchanged)?

Given the crediting rate (i.e., roll-up) available with Product B we can state with certainty that a suitable incentive (one that will leave the client better-off than his or her existing situation) could be less than \$70k (the amount



required to “even out” the income benefit base for both products) and must be higher than \$2k (the minimum to even out the death benefit base).

It also appears that any incentive amount will increase the total value of the transaction, but it is not quite clear at what incentive level the income-generating capabilities of Product A would be matched.

If one is to take a (qualitative) guess, a buyout offer of \$35k to \$40k should be enough, given that the crediting rate in Product B can come close to matching the benefit base values in Product A and be in a better position to lock in future market gains.

### b. Quantitative Assessment for Jill (Economic Valuation)

For this buyout case, we apply the valuation process and examine different cash incentive amounts and their respective effects on the decision and outcome of transaction.

**Figure 12: Assessing a \$15k buyout offer for Jill**

	Product A (old)		Product B (new)	
	Value	$\sigma$	Value	$\sigma$
Lapse / Surrender	\$69,400	28%	\$67,500	37%
Death Benefit	\$30,700	45%	\$41,300	42%
Income Benefit	\$92,500	14%	\$80,600	18%
<b>Economic Value</b>	<b>\$192,600</b>	<b>29%</b>	<b>\$189,400</b>	<b>36%</b>
<b>Net Economic Value: (\$3,200)</b>				

In this case, the results of our quantitative analysis demonstrate that \$15k is not a significant enough of an offer to switch from Product A to Product B. Not only does the economic value *decrease*, but the *uncertainty* around that value increases as well. Also, the increase in death value is not sufficient to classify this as a beneficial transaction. The income benefit with the existing product is superior, partly because of the higher withdrawal rate and partly because the roll-up feature in the new product was not enough to bridge the gap between the benefit base values of the existing and proposed products.

In terms of *legacy*, there is an increase in the death benefit value after the transaction, along with a corresponding decrease in uncertainty. Overall, \$15k may be a sufficient offer if the objective was to achieve a higher legacy value.

However, from the *income* point of view (and regardless of incentive and the better income specifications of Product B), the accumulated income benefit value in Product A prevails. The uncertainty around the income value is also lower (which is positive), thus making Product A in this situation superior.

**Figure 13: Assessing buyout offers for Jill — \$15k, \$20k & \$30k**

	Product A		Product B @ 15k		Product B @ 20k		Product B @ 30k	
	Value	$\sigma$	Value	$\sigma$	Value	$\sigma$	Value	$\sigma$
Lapse / Surrender	\$69,400	28%	\$67,500	37%	\$69,300	37%	\$73,000	37%
Death Benefit	\$30,700	45%	\$41,300	42%	\$42,400	42%	\$44,600	42%
Income Benefit	\$92,500	14%	\$80,600	18%	\$82,800	18%	\$87,100	18%
<b>Economic Value</b>	<b>\$192,600</b>	<b>29%</b>	<b>\$189,400</b>	<b>36%</b>	<b>\$194,500</b>	<b>36%</b>	<b>\$204,700</b>	<b>36%</b>
			<b>Net Economic Value: (\$3,200)</b>			<b>Net Economic Value: \$1,900</b>	<b>Net Economic Value: \$12,100</b>	

Between \$15k and \$20k, we see a shift into positive net economic value territory and now we consider the investor's preference for income versus the death benefit.

After a \$30k incentive, we observe a higher net economic value. However, there is no significant improvement to the income benefit value as the incentive increases.

Ultimately, with a \$50k offer, all values are better on average. Therefore, this can be considered a great transaction for the client, regardless of the client's objectives in considering the offer.

**Figure 14: Assessing a \$50k buyout offer for Jill**


	Product A (old)		Product B (new)	
	Value	$\sigma$	Value	$\sigma$
Lapse / Surrender	\$69,400	28%	\$80,200	37%
Death Benefit	\$30,700	45%	\$49,100	42%
Income Benefit	\$92,500	14%	\$95,800	18%
<b>Economic Value</b>	<b>\$192,600</b>	<b>29%</b>	<b>\$225,100</b>	<b>36%</b>

**Net Economic Value: \$32,500**

### Another Look at the Results

At this point we can go further into the analysis and take a closer look into what these results are really telling us for Jill. By comparing the distribution of outcomes between Product A and Product B, and displaying them in the form of a histogram (in Figure 15), we can gain additional insight into the probabilities associated with each benefit value:


**Figure 15: Examining the distribution of the Economic Value Components for Product B — \$50k buyout for Jill**



We can conclude from this histogram that the Lapse Value of Product B was higher in 82% of scenarios and by average of \$10.7k, with deviation of \$11.1k. This tells us that in vast majority of cases, our client would have been better off by accepting the buyout offer at \$50,000.

Similarly, we can analyze the death value distribution and confirm that Product B was superior in almost every scenario ran with an average difference of approximately \$18k. This undoubtedly shows that from a legacy standpoint this transaction was greatly beneficial to the client.

In terms of income value, the situation is not that clear. This option value is indeed higher on average, but a closer look into the distribution of possible outcomes provides an additional dimension that merits consideration. In this case, Product B was dominant in 63% of scenarios generated, which is significant but cannot be classified as an absolute success.



This additional analysis is meant to show that an economic trade-off is still present and that there's a range of outcomes. As a result, one has to be very careful when assessing transactions involving multiple variable annuities, especially when living benefit riders are in place. Ultimately, we believe that additional quantitative analysis can be helpful in making more informed decisions which are in the best interest of the client, as well as in compliance with regulatory requirements.

In conclusion: Understanding how the benefit is skewed as well as how widely it is distributed helps tell the story of the potential benefit to the investor.

### c. Quantitative Assessment for Mark (Economic Value)

Now, how does this assessment play out in Mark's situation?

**Figure 16: Assessing a \$15k buyout offer for Mark — \$15k Incentive**

	Product A (old)		Product B (new)	
	Value	$\sigma$	Value	$\sigma$
Lapse / Surrender	\$42,000	25%	\$41,600	36%
Death Benefit	\$36,200	34%	\$63,100	31%
Income Benefit	\$107,000	5%	\$81,900	11%
<b>Economic Value</b>	<b>\$185,200</b>	<b>18%</b>	<b>\$186,600</b>	<b>26%</b>
<b>Net Economic Value: \$1,400</b>				

It appears that this transaction was beneficial based on the final net economic value. However, *observe that the uncertainty around the net economic value also went up*. At this point one has to consider the client's preferences along with the underlying motives for the transaction. For example, one client might be interested in securing a higher level of predictable income in retirement, whereas another might want to keep liquidity along with a larger potential bequest value.

This explanation also applies to offers of \$20k, \$30k and \$40k where the death benefit value continues to increase but the income value is still inferior.

Finally, for \$50k, all of the values for the new product increase, but the income benefit never catches up, as opposed to Jill's case. The death value is increasing, but solely due to a cash bonus. The net economic value is positive, but if Mark's objective is to gain a higher income benefit, then the \$50k incentive received at the exchange also falls short of that objective.

**Figure 17: Assessing a \$50k buyout offer for Mark**

	Product A (old)		Product B (new)	
	Value	$\sigma$	Value	$\sigma$
Lapse / Surrender	\$42,000	25%	\$49,400	36%
Death Benefit	\$36,100	34%	\$74,900	31%
Income Benefit	\$107,100	5%	\$97,300	11%
<b>Economic Value</b>	<b>\$185,200</b>	<b>18%</b>	<b>\$221,600</b>	<b>26%</b>
<b>Net Economic Value: \$36,400</b>				

**d. Summary of Case 2 Results**

Figure 18 summarizes the results and highlights the situations where the qualitative assessment and quantitative analysis do not agree.

**Figure 18: Comparing Products A and B when a cash buyout offer is added**

		Which is better?	
		Qualitative Comparison (Specifications)	Quantitative Comparison (Net Economic Value)
Jill @ \$15k	Surrender Value	A	A
	Death Benefit	A	B
	Income Benefit	A	A
	Overall Benefit	A	A
Jill @ \$50k	Surrender Value	A	B
	Death Benefit	B	B
	Income Benefit	A	B
	Overall Benefit	A	B
Mark @ \$15k	Surrender Value	A	A
	Death Benefit	A	B
	Income Benefit	A	A
	Overall Benefit	A	B
Mark @ \$50k	Surrender Value	A	B
	Death Benefit	B	B
	Income Benefit	A	A
	Overall Benefit	A	B

### **CASE 3: NEW SALE / NEW ASSETS**

An economic benefit assessment can also be performed with the first-time purchase of an annuity. In this case, some aspects of our analysis become simplified due to the nature of the transaction because there are no accumulated benefits from an existing annuity contract. In other words, we do not have the influence of moneyiness associated with the decision—only the mechanics of each product and the associated fees play a role in determining the economic benefit as part of the recommendation.

Again, looking at all three values combined or individually can help align the quantitative assessment with the client's preferences. Even without the benefit of accumulated benefits, higher fees do not necessarily correspond with a lower comparative value against competing products.

#### **a. Qualitative Assessment for Jill and Mark**

With a new sale one has to take a closer comparative look given the fact that all account values and benefit bases start at par. Again, we will compare products A and B, but considering a new sale that chooses between them, not exiting or retaining Product A.

At first glance, one suspects that due to lower fees and higher withdrawal rates that Product A would be preferred to generate future income. Although Product B has an additional crediting rate while in accumulation phase, this is countered with higher base contract and rider fees along with a lower guaranteed withdrawal rate which could theoretically reduce the potential value of the income benefit. The roll-up rate comes into play in a down market and one is inclined to believe that a continuous negative market condition over entire income delay period of four years for Jill will not transpire. As such these two products look close to indistinguishable in terms of income-generating capabilities.

In terms of surrender flexibility, Product B seems to have a shorter and more favorable CDSC schedule. Likewise, due to the lower overall level of fees, one can expect that the legacy value of Product A would be higher. However, one can argue that the lower level of withdrawals in Product B would work in favor in wealth preservation. Ultimately, taking a qualitative approach, one cannot conclusively determine which product should be recommended for sale.

The recommendation becomes even more complicated when one tries to incorporate client preferences and attempts to make a recommendation that would be in the best interest for the client.

## b. Quantitative Assessment for Jill (Economic Valuation)

**Figure 19: Economic Valuation for Jill — New Sale**

Economic Value Component	Product A		Product B	
	Value	$\sigma$	Value	$\sigma$
Lapse / Surrender	\$40,600	38%	\$37,300	37%
Death Benefit	\$27,000	49%	\$22,800	42%
Income Benefit	\$42,400	15%	\$44,600	18%
<b>Economic Value</b>	<b>\$110,000</b>	<b>38%</b>	<b>\$104,700</b>	<b>36%</b>

**Net Economic Value: (\$5,300)**

When looking at the valuation of two new products from a quantitative point of view the story becomes slightly more interesting. One can see that the economic value of Product A is better along with a slightly higher standard deviation. However, the income benefit value for Product B is higher at the expense of trading some value from the death benefit.

In terms of surrender value, even though there is a difference with CDSC schedules, it appears that in the long run both products offer similar flexibility when industry lapse experience is incorporated in our model. In this situation we also see that the crediting rate received within Product B, while deferring income, provides a higher income value despite higher fees paid for the rider.

Higher overall fees within Product B contribute to the lower death benefit value compared to Product A. We can also confirm this by looking at additional statistics within our simulation as we did above in Case 2. In terms of legacy, Product A was better 98% of time, however, it was only superior in 69% of observations when it came to income.

Since these two products perform very differently, it is important to know about Jill's preferences. Performing a thorough quantitative analysis empowers Jill (and her advisor) to make an appropriate choice. The advisor can provide guidance that is in the best interest of the client and at the same time satisfy the compliance and regulatory requirements with the sale of annuities.

### c. Quantitative Assessment for Mark (Economic Valuation)

In Mark's case, the economic valuation analysis is as follows:

In this case, the income value is lower for Product B, but the death benefit value is higher. Overall, the uncertainty of both products is lower than in Jill's case, plus Product A has less variation than B (which is the opposite of Jill's valuation).

**Figure 20: Economic Valuation for Mark — New Sale**

Economic Value Component	Product A		Product B	
	Value	$\sigma$	Value	$\sigma$
Lapse / Surrender	\$22,100	38%	\$23,000	36%
Death Benefit	\$33,900	36%	\$34,900	31%
Income Benefit	\$49,900	7%	\$45,300	11%
<b>Economic Value</b>	<b>\$105,900</b>	<b>26%</b>	<b>\$103,200</b>	<b>26%</b>
<b>Net Economic Value: (\$2,700)</b>				

### d. Summary of Case 3 Results

**Figure 21: Comparing Products A and B — New Sale**

		Which is better?	
		Qualitative Comparison (Specifications)	Quantitative Comparison (Net Economic Value)
Jill	Surrender Value	B	A
	Death Benefit	?	A
	Income Benefit	A	B
	Overall Benefit	?	A
Mark	Surrender Value	B	B
	Death Benefit	?	B
	Income Benefit	A	A
	Overall Benefit	?	A

*Conclusion: Not all products (or clients) are created equal, and matching the client's profile and their retirement situation is necessary to determine the largest economic benefit.*

## ALIGNING VALUATION WITH CURRENT PRACTICES

With our proposed new methodology, we are not suggesting that the industry replace existing illustration and comparative tools, but rather add our method to enhance sales and compliance processes and help fill a gap where the determination of economic benefit to the client may be deficient.

Current illustration practices generally include an assessment across three different market scenarios; a negative average return (or a down market in which only the guarantees kick in), a positive average return, and a single random sequence of events across a period of time (e.g., 30 years). There are advantages and disadvantages of this process. Starting with the bad news: the rules and parameters associated with a living benefit are meant to take advantage of some amount of market volatility and a constant average rate of return may not provide an appropriate representation of how a benefit base (i.e., the shadow account) may operate in a realistic environment. By introducing a random sequence, one can get a better sense of performance against volatility; however, the order of that sequence of returns is but one of an infinite number of possibilities. The good news is that these illustrations provide a simple window into the product that a client may be able to understand.

In this paper, we present an economic valuation process that is supported by a Monte Carlo simulation that relies on several thousand random scenarios to approximate the performance of a rider. However, the presentation of Monte Carlo results “across the kitchen table” to the average investor has traditionally been a challenge. While the current practice is to use average returns or a single sequence, the computation of multiple scenarios is necessary to gauge the overall economic benefit—especially when considering the dynamics of longevity in an actuarial present value. Ultimately, it comes down to how the results are simplified if they are to be presented to a client (assuming that the results of this model and analysis are made available beyond advisor use only). There are plenty of examples of how the results of complex analyses are summarized and communicated in a simple manner. In addition, the information design supporting investment decisions is a growing area of behavioral finance research and practice.

We are able to align the valuation process with a traditional view of an illustration that not only projects the accumulation of fees over time, but also the associated account value, income benefit and the death benefit. In this case, we show two comparative products (“A” and “B”) using common assumptions and pricing variables, which allows an advisor to see how the various benefits, values and fees emerge over time. Graphical representations of the results may help further simplify the assessment.

One fundamental difference with this type of illustration table versus traditional tables is that each year represents a point in time average of multiple scenarios.



## CONCLUSION

Annuities have existed for over two thousand years and the original rationale remains the same: to support retirement or other long-range goals by way of periodic income payments. However, as with any financial instrument, annuities have evolved over time resulting in many variations ... along with some confusion to the general public. Today, the most popular variation of an annuity is essentially a structured product that not only bundles multiple features into a single contract, but also includes more complicated financial instruments (e.g., put options) to help address the behavioral finance barriers in having investors commit a portion of their nest egg to guarantees that would help secure their retirement future.

Here, we propose a process that helps break apart these bundled solutions in a transparent manner that is intended to allow the advisor and their client better understand the value of what they are purchasing. As a VA product can perform quite differently for each and every individual, we contend that a simple comparison of fees and specifications is not sufficient to ascertain what the economic benefit would be to the investor. Compliance and regulatory standards continue to rise for financial professionals in support of their clients, therefore, new tools and processes are required to help meet these obligations so that annuities will continue to play an important role in financial planning ... for the next two thousand years.

## REFERENCES

1. 26 U.S.C §1035 – Certain Exchanges of Insurance Policies.
2. FINRA Rule 2330 – Members’ Responsibilities Regarding Deferred Variable Annuities (2014).
3. FINRA Rule 2111 – Suitability (2014).
4. Huang, H., Milevsky, M. and Salisbury, T. Complete Market Valuation of the Ruin-Contingent Life Annuity (RCLA). *Journal of Risk and Insurance* (January 16, 2009).
5. LIMRA Secure Retirement Institute. U.S Individual Annuity Sales – 2006 – 2015. Retrieved from [www.limra.com/Posts/PR/Data\\_Bank/\\_PDF/2006-2015-Annuities-Sales-Estimates.aspx](http://www.limra.com/Posts/PR/Data_Bank/_PDF/2006-2015-Annuities-Sales-Estimates.aspx)
6. LIMRA Secure Retirement Institute. U.S. Individual Annuity Sales – 2015 Year-End Results. Retrieved from [www.limra.com/uploadedFiles/limra.com/LIMRA\\_Root/Posts/PR/\\_Media/PDFs/2015-Top-20-Rankings.pdf](http://www.limra.com/uploadedFiles/limra.com/LIMRA_Root/Posts/PR/_Media/PDFs/2015-Top-20-Rankings.pdf)
7. LIMRA Secure Retirement Institute. (2014). Variable Annuity Guaranteed Living Benefits Utilization Study: 2012 Owners Experience.
8. Levaux, Janet. (2016, April 5). The ABCs of the DOL Fiduciary Rule. *Think Advisor*. Retrieved from [www.thinkadvisor.com/2016/04/05/the-abcs-of-the-dol-fiduciary-rule](http://www.thinkadvisor.com/2016/04/05/the-abcs-of-the-dol-fiduciary-rule)
9. Milevsky, M. (2006). *The Calculus of Retirement Income: Financial Models for Pension Annuities and Life Insurance*. New York, NY: Cambridge University Press.
10. Milevsky, M., Panyagometh, K. (April 2004). Exchanging Variable Annuities: An Optional Test for Suitability. *Journal of Financial Planning*, 17(4), 56-66.
11. Morgan Stanley. (June 2016). Understanding Variable Annuities. Retrieved from [www.morganstanley.com/assets/pdfs/wealth-management-disclosures/understandingvariableannuities.pdf](http://www.morganstanley.com/assets/pdfs/wealth-management-disclosures/understandingvariableannuities.pdf)
12. U.S. SEC. (April 2011). Variable Annuities: What You Should Know. Retrieved from [www.sec.gov/investor/pubs/varannty.htm](http://www.sec.gov/investor/pubs/varannty.htm)

Case studies and examples contained in this document are for illustrative purposes only and should not be relied upon as advice or recommendations.



## **Contact Information**

CANNEX Financial Exchanges Limited  
1200 Bay Street, Suite 1001  
Toronto, Ontario  
Canada  
M5R 2A5

Phone: (416) 926-0882  
Toll Free: (800) 387-1269  
Fax: (416) 926-0706

Email: [cannex@cannex.com](mailto:cannex@cannex.com)

**[www.cannex.com](http://www.cannex.com)**